Undisclosed RIPTAC for p53 Y220C mutant tumor / J&J - LARVOL DELTA

An orally bioavailable RIPTAC™ therapeutic for p53 Y220C mutant tumors (AACR 2025) - "Moreover, we have demonstrated that the RIPTAC is orally bioavailable and in vivo studies investigating PD modulation and efficacy in a p53Y220C tumor model are ongoing. Taken together, these data support advancing the p53Y220C RIPTAC program toward the clinic as a potential therapeutic option for patients with tumors that harbor this historically undruggable mutation."

Late-breaking abstract • Oncology